CARLSMED, INC.
Carlsmed develops and sells AI-enabled personalized technology for lumbar and cervical spine fusion surgery. Its aprevo Technology Platform combines software that uses diagnostic imaging and algorithms to create personalized surgical plans with patient-specific interbody implants and single-use surgical instruments. The platform also collects post-operative data to inform surgical planning. Carlsmed’s products are designed for hospitals and ambulatory surgical centers, and its customers include surgeons treating patients with degenerative disc disease and adult spinal deformity. Its corra Cervical Plating System is part of its cervical platform. Carlsmed makes money by selling personalized implant devices and marketing the aprevo platform through a direct sales team and independent sales agents. The company’s current commercial focus is the U.S. market. It is headquartered in Carlsbad, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Biotech and healthcare stocks surged after strong quarterly results. KORU Medical (KRMD) reported 11.2% revenue growth, raising FY26 guidance. Carlsmed (CARL) saw 65% revenue growth, also raising guidance. Azenta (AZTA) reported 5% revenue growth and issued FY27 outlook. Capricor (CAPR) rose on FDA review progress for its DMD therapy.
Xeris Biopharma (XERS) and Carlsmed (CARL) shares hit all-time highs after strong Q3 earnings. Barclays called XERS' Q3 'impressive,' raising its target to $18. XERS expects Recorlev sales to hit $1B earlier. BTIG raised CARL's target to $26, citing strong growth prospects. XERS shares up 3.8%, CARL up 22%.
Truist Securities kept Carlsmed's rating at Buy and increased its price target to $23 from $20, suggesting a 56.4% upside from the Nov 10 close of $14.71, according to the firm.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning CARL (CARLSMED, INC.). Coverage has skewed bullish: 9 bullish, 0 neutral, and 0 bearish.
Recent CARL coverage spans financial news, earnings and market movers.
In the last 30 days, CARL insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($15K). The most active reporter was Bertolini Jeffrey, Chief Operating Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Strong top-line acceleration and higher FY26 guidance are likely the main catalysts for the sharp move, despite a widening net loss.
Strong top‑line beat and higher guidance support continued rally.
Truist Securities kept Carlsmed's rating at Buy and increased its price target to $23 from $20, suggesting a 56.4% upside from the Nov 10 close of $14.71, according to the firm.
Needham kept its Buy rating on Carlsmed and increased its price target to $22 from $17, suggesting a 49.6% upside from the Nov 10 close of $14.71.
BTIG reaffirmed its Buy rating for Carlsmed and increased its price target to $26 from $24, representing an 8.3% rise. This target suggests a 76.8% upside from the Nov 10 closing price of $14.71.
AlphAI scores every news story that mentions CARL with an AI model for sentiment and relevance, and aggregates insider trades from CARLSMED, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech and healthcare stocks surged after strong quarterly results. KORU Medical (KRMD) reported 11.2% revenue growth, raising FY26 guidance. Carlsmed (CARL) saw 65% revenue growth, also raising guidance. Azenta (AZTA) reported 5% revenue growth and issued FY27 outlook. Capricor (CAPR) rose on FDA review progress for its DMD therapy.
Xeris Biopharma (XERS) and Carlsmed (CARL) shares hit all-time highs after strong Q3 earnings. Barclays called XERS' Q3 'impressive,' raising its target to $18. XERS expects Recorlev sales to hit $1B earlier. BTIG raised CARL's target to $26, citing strong growth prospects. XERS shares up 3.8%, CARL up 22%.
Truist Securities kept Carlsmed's rating at Buy and increased its price target to $23 from $20, suggesting a 56.4% upside from the Nov 10 close of $14.71, according to the firm.
Needham kept its Buy rating on Carlsmed and increased its price target to $22 from $17, suggesting a 49.6% upside from the Nov 10 close of $14.71.
BTIG reaffirmed its Buy rating for Carlsmed and increased its price target to $26 from $24, representing an 8.3% rise. This target suggests a 76.8% upside from the Nov 10 closing price of $14.71.
Carlsmed (NASDAQ:CARL) plans to enroll patients in a registry for its aprevo Cervical product in Q4. The company expects a change in reimbursement coding to boost lumbar procedure growth. Carlsmed launched its aprevo posterior bilateral procedure in mid-October and plans to launch its corra cervical plating system soon. Q3 gross margin improved to 77.3%, but adjusted EBITDA remained negative at -$7.3M. The company ended Q3 with $80.3M in cash and investments.
CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (
Goldman Sachs added Deutsche Bank (DB) and Carlsberg (CARL) to its European conviction list, citing profitability and growth prospects. It removed HSBC (HSBA), Haleon (HLN), and CTP. Deutsche Bank is expected to improve returns, while Carlsberg is seen benefiting from acquisitions. Haleon, trading near a 52-week low, was removed despite being deemed undervalued. Deutsche Bank upgraded Haleon's rating to Hold with a slightly lower price target.
Carlsmed, Inc. (Nasdaq: CARL) will release its Q3 2026 financial results on Nov. 10, 2026, after market close. A conference call and webcast will follow at 1:30 PM Pacific Time. The company focuses on AI-enabled personalized spine surgery solutions.
Carlsmed, Inc. (CARL) has launched its aprevo Lumbar Bi-lateral Posterior System in the U.S. after a limited market evaluation. The company announced this at the North American Spine Society (NASS) event. Carlsmed aims to expand its personalized spine platform with this new product.
